MA47314B1 - Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide d'agonistes du récepteur glp-1 conjugués à des antagonistes du récepteur peptidique inhibiteur gastrique (gipr) - Google Patents

Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide d'agonistes du récepteur glp-1 conjugués à des antagonistes du récepteur peptidique inhibiteur gastrique (gipr)

Info

Publication number
MA47314B1
MA47314B1 MA47314A MA47314A MA47314B1 MA 47314 B1 MA47314 B1 MA 47314B1 MA 47314 A MA47314 A MA 47314A MA 47314 A MA47314 A MA 47314A MA 47314 B1 MA47314 B1 MA 47314B1
Authority
MA
Morocco
Prior art keywords
glp
gipr
treating
receptor
antagonists
Prior art date
Application number
MA47314A
Other languages
English (en)
Other versions
MA47314A (fr
Inventor
Kelvin Sham
Jing Xu
Shanaka STANISLAUS
Bin Wu
Junming Yie
Murielle M. VENIANT-ELLISON
Leslie P. Miranda
Chawita NETIROJJANAKUL
Yuan Cheng
Jerry Ryan Holder
James R. Falsey
Bradley J. Herberich
Shu-Chen Lu
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61832572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA47314(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of MA47314A publication Critical patent/MA47314A/fr
Publication of MA47314B1 publication Critical patent/MA47314B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6847—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a hormone or a hormone-releasing or -inhibiting factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés de traitement de maladies et de troubles métaboliques à l'aide d'une composition comprenant une protéine de liaison à l'antigène spécifique du polypeptide GIPR conjugué à un agoniste du récepteur du glucagon-like peptide-1 (GLP-1). Dans divers modes de réalisation, la maladie ou le trouble métabolique est le diabète de type 2, l'obésité, la dyslipidémie, la glycémie élevée, le taux d'insuline élevé et la néphropathie diabétique. Dans certains modes de réalisation, la composition comprend un anticorps ou un fragment fonctionnel de celui-ci comprenant une cystéine au niveau d'un ou de plusieurs sites de conjugaison, l'agoniste du récepteur du GLP-1 étant conjugué à l'anticorps ou à un fragment fonctionnel de celui-ci par l'intermédiaire de la chaîne latérale du résidu cystéine.
MA47314A 2017-01-17 2018-01-16 Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide d'agonistes du récepteur glp-1 conjugués à des antagonistes du récepteur peptidique inhibiteur gastrique (gipr) MA47314B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762447332P 2017-01-17 2017-01-17
EP18714635.2A EP3570885B1 (fr) 2017-01-17 2018-01-16 Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide d'agonistes du récepteur glp-1 conjugués à des antagonistes du récepteur peptidique inhibiteur gastrique (gipr)
PCT/US2018/013918 WO2018136440A1 (fr) 2017-01-17 2018-01-16 Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide d'agonistes du récepteur du glp-1 conjugués à des antagonistes du récepteur du peptide inhibiteur gastrique (gipr)

Publications (2)

Publication Number Publication Date
MA47314A MA47314A (fr) 2019-11-27
MA47314B1 true MA47314B1 (fr) 2025-01-31

Family

ID=61832572

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47314A MA47314B1 (fr) 2017-01-17 2018-01-16 Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide d'agonistes du récepteur glp-1 conjugués à des antagonistes du récepteur peptidique inhibiteur gastrique (gipr)

Country Status (38)

Country Link
US (3) US10905772B2 (fr)
EP (2) EP4480537A3 (fr)
JP (3) JP7175899B2 (fr)
KR (3) KR102781241B1 (fr)
CN (2) CN118079021A (fr)
AR (2) AR110751A1 (fr)
AU (2) AU2018210858B2 (fr)
BR (1) BR112019014588A2 (fr)
CA (1) CA3049023A1 (fr)
CL (1) CL2019001963A1 (fr)
CO (1) CO2019007685A2 (fr)
CR (2) CR20190380A (fr)
DK (1) DK3570885T3 (fr)
EA (1) EA201991721A1 (fr)
ES (1) ES3009462T3 (fr)
FI (1) FI3570885T3 (fr)
HR (1) HRP20241563T1 (fr)
HU (1) HUE069334T2 (fr)
IL (2) IL267660B2 (fr)
JO (1) JOP20190177B1 (fr)
LT (1) LT3570885T (fr)
MA (1) MA47314B1 (fr)
MD (1) MD3570885T2 (fr)
MX (2) MX2019008462A (fr)
NZ (1) NZ754937A (fr)
PE (2) PE20250777A1 (fr)
PH (1) PH12019501656A1 (fr)
PL (1) PL3570885T3 (fr)
PT (1) PT3570885T (fr)
RS (1) RS66291B1 (fr)
SA (1) SA519402246B1 (fr)
SG (1) SG11201906525SA (fr)
SI (1) SI3570885T1 (fr)
SM (1) SMT202400502T1 (fr)
TW (1) TWI708613B (fr)
UY (1) UY37568A (fr)
WO (1) WO2018136440A1 (fr)
ZA (1) ZA201904287B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117106085A (zh) 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
EP4480537A3 (fr) 2017-01-17 2025-03-12 Amgen Inc. Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide d'agonistes du récepteur glp-1 conjugués à des antagonistes du récepteur du peptide inhibiteur gastrique (gipr)
CA3062194A1 (fr) 2017-06-20 2018-12-27 Amgen Inc. Methode de traitement ou de reduction de troubles metaboliques a l'aide de proteines de liaison au recepteur du peptide inhibiteur gastrique (gipr) en association avec des agonist es du glp-1
JP7250706B2 (ja) 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
MA68842B1 (fr) 2017-08-04 2025-01-31 Amgen Inc. Procédé de conjugaison de cys-mabs
JP7536030B2 (ja) 2019-03-08 2024-08-19 アムジエン・インコーポレーテツド 増殖分化因子１５併用療法
CN112521501A (zh) * 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
US12054551B2 (en) 2020-07-02 2024-08-06 Sanofi FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates thereof with GLP-1R agonistic peptides
JP2023542295A (ja) 2020-09-14 2023-10-06 リジェネロン ファーマシューティカルズ，インク． Ｇｌｐ１ペプチド模倣薬を含む抗体薬物複合体及びその使用
CN116171164A (zh) 2020-10-17 2023-05-26 太阳医药工业有限公司 Glp-1/gip双重激动剂
EP4351627A4 (fr) 2021-05-21 2025-06-04 Yuhan Corporation Composition pour polythérapie comprenant un variant de facteur de différenciation de croissance 15 et un agoniste du récepteur du peptide 1 de type glucagon
EP4352104A4 (fr) * 2021-06-09 2025-06-04 Swiftnovo Therapeutics Inc. Agents thérapeutiques et méthodes de traitement ou de réduction de troubles métaboliques
CA3243669A1 (fr) * 2022-03-11 2023-09-14 Regeneron Pharmaceuticals, Inc. Conjugués anticorps-médicament anti-glp1r comprenant des peptidomimétiques de glp1 et leurs utilisations
AU2023337288A1 (en) * 2022-09-08 2025-03-13 Gmax Biopharm Llc Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof
KR102679905B1 (ko) * 2022-10-12 2024-07-02 서울대학교병원 Gipr 마커를 이용한 설폰요소제 의존성 예측용 조성물 및 그 예측 방법
US20260139314A1 (en) * 2022-10-12 2026-05-21 Seoul National University Hospital Composition and method for predicting sulfonylurea dependency using gipr marker
TW202432600A (zh) * 2022-11-07 2024-08-16 美商安進公司 用於治療肥胖症之方法
WO2024123812A1 (fr) * 2022-12-05 2024-06-13 Shattuck Labs, Inc. Protéines de fusion pour le traitement de maladies cardiométaboliques
WO2024209050A1 (fr) 2023-04-05 2024-10-10 Antag Therapeutics Aps Modulateurs de l'activité du gip et intolérance orthostatique
EP4727963A2 (fr) * 2023-06-14 2026-04-22 Fractyl Health, Inc. Thérapies géniques pour troubles métaboliques
KR20260052949A (ko) 2023-08-11 2026-04-20 암젠 인크 고체상 항체 접합 방법
CN122094712A (zh) 2023-10-31 2026-05-26 山东博安生物技术股份有限公司 Gipr阻断型抗体及其抗体偶联物
US20250163168A1 (en) 2023-11-17 2025-05-22 Pfizer Inc. Novel antibodies and antibody conjugates for the treatment of metabolic disorders
WO2025199030A1 (fr) * 2024-03-18 2025-09-25 Amgen Inc. Agonistes du récepteur glp-1 et leur utilisation médicale
US20260077054A1 (en) * 2024-09-18 2026-03-19 Helicore Biopharma, Inc. Combinations of anti-gip antibodies and incretins and uses thereof
WO2026093993A1 (fr) 2024-11-01 2026-05-07 Janssen Biotech, Inc. Procédés et systèmes pour ciblage métabolique et cellulaire multispécifiques amélioré

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (fr) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipides en phase aqueuse
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (fr) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Composition pharmaceutique contenant de l'urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
EP0281604B1 (fr) 1986-09-02 1993-03-31 Enzon Labs Inc. Molecules de liaison de chaines de polypeptide simples
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO1991018982A1 (fr) 1990-06-05 1991-12-12 Immunex Corporation Recepteurs de l'interleukine-1 de type ii
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
JPH06508035A (ja) 1991-06-14 1994-09-14 ディーエヌエックス　コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
EP0593592B1 (fr) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Copolymere en masse segmentee a cristaux liquides thermotropiques
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
CA2169298A1 (fr) 1993-09-10 1995-03-16 Martin Chalfie Utilisations d'une proteine fluorescente verte
WO1995021191A1 (fr) 1994-02-04 1995-08-10 William Ward Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
CA2219361C (fr) 1995-04-27 2012-02-28 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
DE69740096D1 (de) 1996-08-08 2011-02-17 Amylin Pharmaceuticals Inc Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
AU5518798A (en) 1996-12-03 1998-06-29 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
US7091183B1 (en) 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
EP1972194A1 (fr) 1996-12-03 2008-09-24 Amgen Fremont Inc. Mammifères transgéniques disposant d'un loci ig comprenant plusieurs régions vh et vk et anticorps produits à partir de ceux-ci
ATE290205T1 (de) 1996-12-12 2005-03-15 Prolume Ltd Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen
JP4798814B2 (ja) 1997-01-07 2011-10-19 アミリン・ファーマシューティカルズ，インコーポレイテッド 食物摂取低減用のエキセンジンおよびそのアゴニストの使用
CA2196496A1 (fr) 1997-01-31 1998-07-31 Stephen William Watson Michnick Epreuve de complementation de fragments de proteines pour la detection d'interactions entre proteines
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ES2293688T5 (es) 1997-08-08 2011-05-04 Amylin Pharmaceuticals, Inc. Nuevos compuestos análogos de la exendina.
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
CA2309356C (fr) 1997-11-14 2010-09-21 Amylin Pharmaceuticals, Inc. Nouveaux composes agonistes de l'exendine
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
NZ504258A (en) 1997-11-14 2002-12-20 Amylin Pharmaceuticals Inc Exendin 3 and 4 agonist compounds for the treatment of diabetes
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
WO1999040788A1 (fr) 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Effets inotropiques et diuretiques de l'extendine et du gpl-1
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
DE69926007T2 (de) 1998-10-07 2005-12-29 Medical College Of Georgia Research Institute, Inc. Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon
PL208751B1 (pl) 1998-12-07 2011-06-30 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków
CA2358107C (fr) 1998-12-22 2011-08-23 Eli Lilly And Company Formulation de longue conservation de peptide-1 de type glucagon
JP2002538084A (ja) 1999-01-14 2002-11-12 アミリン・ファーマシューティカルズ，インコーポレイテッド グルカゴンを抑制する方法
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
RU2242244C2 (ru) 1999-01-14 2004-12-20 Амилин Фармасьютикалз, Инк. Новые композиции агонистов эксендина и способы их введения
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
ATE272650T1 (de) 1999-03-29 2004-08-15 Uutech Ltd Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
AU1190101A (en) 1999-09-27 2001-04-30 Regents Of The University Of California, The Engineering antibodies that bind irreversibly
WO2001051078A1 (fr) 2000-01-10 2001-07-19 Amylin Pharmaceuticals, Inc. Utilisation d'exendines et d'agonistes de ces dernieres pour moduler les taux de triglycerides et pour traiter la dyslipidemie
ATE264870T1 (de) 2000-01-27 2004-05-15 Lilly Co Eli Verfahren zur lösung von glucagon-ähnlichen peptid-1 (glp-1) verbindungen
WO2001087341A1 (fr) 2000-05-16 2001-11-22 Sanwa Kagaku Kenkyusho Co.,Ltd. Agents permettant de prevenir ou d'ameliorer l'insulino-resistance et/ou l'obesite
ES2464532T3 (es) 2001-04-19 2014-06-03 The Scripps Research Institute Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa
US20050159379A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
JP4566459B2 (ja) 2001-06-07 2010-10-20 株式会社日立製作所 表示装置
WO2003055914A2 (fr) 2001-12-21 2003-07-10 7Tm Pharma A/S Recepteurs modifies pour la recherche de ligands therapeutiques
AU2003208945B2 (en) 2002-02-20 2008-05-01 Emisphere Technologies, Inc Method for administering GLP-1 molecules
JPWO2003097031A1 (ja) 2002-05-22 2005-09-15 株式会社三和化学研究所 メチリデンヒドラジド化合物を有効成分とする、肥満の予防又は改善剤
AU2003248676A1 (en) 2002-06-15 2003-12-31 Enteromed, Inc. Treatment of non-alcoholic fatty liver disease
JP2006213598A (ja) 2003-03-19 2006-08-17 Sanwa Kagaku Kenkyusho Co Ltd ピラゾロピリミジン化合物及びその用途
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
WO2005021022A2 (fr) 2003-09-01 2005-03-10 Novo Nordisk A/S Formulations de peptides stables
KR20140011431A (ko) 2004-02-11 2014-01-28 아밀린 파마슈티칼스, 엘엘씨. 선택가능한 특성을 갖는 하이브리드 폴리펩티드
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US7991890B2 (en) 2004-09-30 2011-08-02 Microsoft Corporation Game console communication with a device
NZ554386A (en) 2004-10-25 2009-12-24 Cytos Biotechnology Ag Gastric inhibtory polypeptide (GIP) antigen arrays with VLPs and uses thereof
JP2008525452A (ja) 2004-12-22 2008-07-17 イーライ リリー アンド カンパニー Ｇｌｐ−１類似体融合蛋白質製剤
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CA2597649A1 (fr) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Analogues de gip et polypeptides hybrides de gip aux proprietes selectionnables
EP1882044A1 (fr) 2005-05-11 2008-01-30 sanofi-aventis Utilisation du polymorphisme d'un promoteur gip
CN101180081B (zh) 2005-05-25 2015-08-26 诺沃-诺迪斯克有限公司 稳定的多肽制剂
US20090170762A1 (en) 2005-09-08 2009-07-02 Uutech Limited Treatment of Diabetes Related Obesity
AU2007227202B2 (en) 2006-03-21 2013-08-22 Amylin Pharmaceuticals, Llc Peptide-peptidase inhibitor conjugates and methods of using same
EP2007804B1 (fr) 2006-04-20 2014-06-18 Amgen, Inc Composés de glp-1
AU2007240315A1 (en) 2006-04-20 2007-11-01 Amgen Inc. GLP-1 compound/glucagon antibody compositions
WO2008006113A2 (fr) 2006-07-07 2008-01-10 The Texas A & M University System Dérivés atypiques de bélactosine en tant qu'agents thérapeutiques/sondes biologiques et leur synthèse
EP2068910A2 (fr) 2006-08-04 2009-06-17 Amylin Pharmaceuticals, Inc. Utilisation d'exendines et d'agonistes d'exendines et d'agonistes du récepteur glp-1 pour modifier la dimension de particule et la composition de sous-classe de lipoprotéines
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
JP5399244B2 (ja) 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
US8598314B2 (en) 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
US20090144162A1 (en) 2007-11-29 2009-06-04 Neil Milne Transaction Security Method and Apparatus
GB0814068D0 (en) 2008-08-01 2008-09-10 Univ Ulster Active immunisation against GIP
ES2574835T3 (es) 2008-08-07 2016-06-22 Ipsen Pharma S.A.S. Análogos del polipéptido insulinotrópico dependiente de glucosa
KR20130133103A (ko) 2008-08-07 2013-12-05 입센 파마 에스.에이.에스 Ｎ-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(ｇｉｐ)의 유사체
CA2732949C (fr) 2008-08-07 2016-12-20 Ipsen Pharma S.A.S. Analogues de polypeptide insulinotrope glucose-dependant
CA2733005C (fr) 2008-08-07 2016-09-27 Ipsen Pharma S.A.S. Analogues tronques de polypeptide insulinotrope glucose-dependant
WO2010016936A1 (fr) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Compositions pharmaceutiques d'analogues de polypeptide insulinotrope glucose-dépendant
WO2011014680A2 (fr) 2009-07-31 2011-02-03 The Board Of Trustees Of The Leland Stanford Junior University Variantes du peptide inhibiteur gastrique et leurs utilisations
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
US20130344524A1 (en) 2011-03-08 2013-12-26 Sanwa Kagaku Kenkyusho Co., Ltd. Analysis method
KR102002783B1 (ko) 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
EP3539982B1 (fr) 2011-12-23 2025-02-19 Pfizer Inc. Régions constantes d'anticorps modifiés pour conjugaison spécifique à un site, et leurs procédés et utilisations
EP2851429B1 (fr) 2012-05-18 2019-07-24 Adda Biotech Inc. Protéine et conjugué protéique pour le traitement du diabète et applications associées
MX2015002985A (es) 2012-09-07 2015-06-22 Sanofi Sa Proteinas de fusion para el tratamiento de un sindrome metabolico.
WO2014100913A1 (fr) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Amélioration de la demi-vie d'un polypeptide thérapeutique par fusion avec une protéine d'échafaudage trimère via un espaceur
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
WO2015022420A1 (fr) 2013-08-16 2015-02-19 Medimmune Limited Agonistes doubles de récepteur de gip et glp-1 pour le traitement du diabète
US20160297883A1 (en) * 2013-12-04 2016-10-13 Innovative Targeting Solutions, Inc. G-protein coupled receptor agonists and methods
EP3079722B1 (fr) 2013-12-13 2021-03-24 Novo Nordisk Health Care AG Procédé pour la conjugaison de protéines thioéther
ES2846099T3 (es) 2013-12-17 2021-07-28 Mhs Care Innovation Llc Composiciones y métodos para tratar la acumulación de tejidos grasos
ES2719584T3 (es) 2014-04-11 2019-07-11 Medimmune Llc Compuestos conjugados que comprenden anticuerpos modificados por ingeniería genética con cisteína
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
US10097078B2 (en) 2014-10-21 2018-10-09 Toshiba International Corporation Multi-mode energy router
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
TWI783244B (zh) 2015-06-22 2022-11-11 美商美國禮來大藥廠 升糖素及glp-1共激動劑化合物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CN117106085A (zh) 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
EP4480537A3 (fr) 2017-01-17 2025-03-12 Amgen Inc. Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide d'agonistes du récepteur glp-1 conjugués à des antagonistes du récepteur du peptide inhibiteur gastrique (gipr)
US20180237095A1 (en) 2017-02-23 2018-08-23 Motive Power Industry Co., Ltd. Two-wheel suspension mechanism
CA3062194A1 (fr) 2017-06-20 2018-12-27 Amgen Inc. Methode de traitement ou de reduction de troubles metaboliques a l'aide de proteines de liaison au recepteur du peptide inhibiteur gastrique (gipr) en association avec des agonist es du glp-1
JP7250706B2 (ja) 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
MA68842B1 (fr) 2017-08-04 2025-01-31 Amgen Inc. Procédé de conjugaison de cys-mabs

Also Published As

Publication number Publication date
JP7574253B2 (ja) 2024-10-28
EP3570885B1 (fr) 2024-09-18
ZA201904287B (en) 2025-10-29
AU2018210858B2 (en) 2025-02-20
DK3570885T3 (da) 2024-12-16
UY37568A (es) 2018-07-31
MD3570885T2 (ro) 2025-03-31
EP4480537A2 (fr) 2024-12-25
JP2020506900A (ja) 2020-03-05
JP7175899B2 (ja) 2022-11-21
KR102697797B1 (ko) 2024-08-27
WO2018136440A1 (fr) 2018-07-26
CN110662558B (zh) 2024-04-09
JP2022184880A (ja) 2022-12-13
CR20190380A (es) 2019-11-07
PH12019501656A1 (en) 2019-10-28
US20250121056A1 (en) 2025-04-17
CN118079021A (zh) 2024-05-28
SMT202400502T1 (it) 2025-01-14
ES3009462T3 (en) 2025-03-27
MX2019008462A (es) 2019-11-21
MX2024015311A (es) 2025-01-09
SA519402246B1 (ar) 2023-02-15
EP4480537A3 (fr) 2025-03-12
HRP20241563T1 (hr) 2025-01-31
PL3570885T3 (pl) 2025-03-17
KR20250038835A (ko) 2025-03-19
FI3570885T3 (fi) 2024-12-18
SG11201906525SA (en) 2019-08-27
US20210154318A1 (en) 2021-05-27
PE20191467A1 (es) 2019-10-16
MA47314A (fr) 2019-11-27
EP3570885A1 (fr) 2019-11-27
NZ754937A (en) 2023-04-28
US12214051B2 (en) 2025-02-04
CN110662558A (zh) 2020-01-07
KR20190104158A (ko) 2019-09-06
CR20230302A (es) 2023-08-25
TW201838648A (zh) 2018-11-01
KR20240131457A (ko) 2024-08-30
JOP20190177A1 (ar) 2019-07-16
JP2025011265A (ja) 2025-01-23
KR102781241B1 (ko) 2025-03-14
US10905772B2 (en) 2021-02-02
AR135084A2 (es) 2026-06-10
LT3570885T (lt) 2024-12-27
CL2019001963A1 (es) 2020-04-03
IL313587A (en) 2024-08-01
AU2018210858A1 (en) 2019-07-18
SI3570885T1 (sl) 2025-02-28
AR110751A1 (es) 2019-05-02
TWI708613B (zh) 2020-11-01
AU2025201348A1 (en) 2025-03-20
HUE069334T2 (hu) 2025-02-28
IL267660A (en) 2019-08-29
RS66291B1 (sr) 2025-01-31
EA201991721A1 (ru) 2020-04-08
CO2019007685A2 (es) 2019-07-31
CA3049023A1 (fr) 2018-07-26
BR112019014588A2 (pt) 2020-02-18
IL267660B1 (en) 2024-07-01
US20180311372A1 (en) 2018-11-01
IL267660B2 (en) 2024-11-01
JOP20190177B1 (ar) 2024-04-18
PE20250777A1 (es) 2025-03-14
PT3570885T (pt) 2024-12-16

Similar Documents

Publication Publication Date Title
EA201991721A1 (ru) Способ лечения или облегчения метаболических нарушений с использованием агонистов рецептора glp-1, конъюгированных с антагонистами рецептора желудочного ингибиторного пептида (gipr)
Sparre‐Ulrich et al. Species‐specific action of (Pro3) GIP–A full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
Ørgaard et al. The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
Vilsbøll et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
Hansen et al. N‐terminally and C‐terminally truncated forms of glucose‐dependent insulinotropic polypeptide are high‐affinity competitive antagonists of the human GIP receptor
Lucey et al. Disconnect between signalling potency and in vivo efficacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists
Wootten et al. Allostery and biased agonism at class BG protein-coupled receptors
Gasbjerg et al. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Vilsbøll et al. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
EA201891323A1 (ru) Способ лечения или облегчения метаболических нарушений с использованием белков, связывающих рецептор желудочного ингибиторного пептида (gipr), в комбинации с агонистами glp-1
Tornehave et al. Expression of the GLP-1 receptor in mouse, rat, and human pancreas
Baggio et al. A recombinant human glucagon-like peptide (GLP)-1–albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor–dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis
MX2019013919A (es) Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
Chepurny et al. Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors
EP4353250A3 (fr) Methode de traitement ou d'amelioration de troubles metaboliques utilisant des proteines de liaison antagonistes pour des proteines de fusion agonistes du recepteur du peptide inhibiteur gastrique (gipr)/glp-1
Deacon Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors
Jung et al. Expression of glucagon-like Peptide-1 receptor in papillary thyroid carcinoma and its clinicopathologic significance
JP2022177118A (ja) 糖尿病のためのｇｉｐ／ｇｌｐ１共アゴニストを使用する方法
Albrechtsen et al. Dynamics of glucagon secretion in mice and rats revealed using a validated sandwich ELISA for small sample volumes
Schaarschmidt et al. Influence of the hinge region and its adjacent domains on binding and signaling patterns of the thyrotropin and follitropin receptor
Lewandowski et al. Evaluating glucose-dependent insulinotropic polypeptide and glucagon as key regulators of insulin secretion in the pancreatic islet
US20140378374A1 (en) Methods of treatment
EA201991583A1 (ru) Способ лечения или облегчения метаболических нарушений с использованием белков, связывающих рецептор желудочного ингибиторного пептида (gipr), в комбинации с агонистами glp-1
Stephen et al. Modulation of the Pancreatic Hormone, Glucagon by the Gut Peptide, GLP-1: Controversies, Challenges and Future Directions
Fukuda Gut hormone GIP drives hypothalamic pathogenesis of obesity via Epac-Rap1 signaling